Krystal Biotech Inc expected to post a loss of $1.32 a share - Earnings Preview

Krystal Biotech

24/02/2023 18:26

* Krystal Biotech Inc  KRYS.OQ   KRYS.O  is expected to show
no
change in quarterly revenue when it reports  results on February
27 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Krystal Biotech Inc
is
for a loss of $1.32 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Krystal
Biotech
Inc is $106​, above​ its last closing price of $78.24. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -1.23       -1.22      -1.17     Beat    3.9
 Jun. 30 2022  -0.99       -1.02      -1.10     Missed  -8.3
 Mar. 31 2022  -1.06       -1.05      -0.99     Beat    5.6​
 Dec. 31 2021  -0.75       -0.73      -0.95     Missed  -29.7
 ​​Sep.        -0.76       -0.74      -0.70     Beat    5.2
 30 2021                                                
 Jun. 30 2021  -0.79       -0.76      -0.74     Beat    2.3​
 Mar. 31 2021  -0.54       -0.56      -0.67     Missed  -20.3
 Dec. 31 2020  -0.59       -0.59      -0.53     Beat    10.7
 This summary was machine generated February 24 at 18:26 GMT. 
All figures in US dollars  unless otherwise stated